Search

Your search keyword '"Mondelli, Mario U."' showing total 62 results
Start Over Author "Mondelli, Mario U." Publisher elsevier bv
62 results on '"Mondelli, Mario U."'

4. Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper

Author

Marjot, Thomas, primary, Eberhardt, Christiane S., additional, Boettler, Tobias, additional, Belli, Luca S., additional, Berenguer, Marina, additional, Buti, Maria, additional, Jalan, Rajiv, additional, Mondelli, Mario U., additional, Moreau, Richard, additional, Shouval, Daniel, additional, Berg, Thomas, additional, and Cornberg, Markus, additional

Published
2022
Full Text
View/download PDF

9. Patients with chronic hepatitis C receiving treatment with direct acting antivirals: How is this population changing?

Author

Lombardi, Andrea, primary, Colaneri, Marta, additional, Vijayagopal, Kesav Aditya, additional, Sambo, Margherita, additional, Legnazzi, Patrizia, additional, Sacchi, Paolo, additional, Zuccaro, Valentina, additional, Maiocchi, Laura, additional, Maserati, Renato, additional, Gulminetti, Roberto, additional, Pagnucco, Layla, additional, Novati, Stefano, additional, Zanaboni, Domenico, additional, Michelone, Giuseppe, additional, Ludovisi, Serena, additional, Mondelli, Mario U., additional, and Bruno, Raffaele, additional

Published
2021
Full Text
View/download PDF

10. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

Author

National Institutes of Health (US), National Health Service (UK), Boettler, Tobias [0000-0002-1195-055X], Maticic, Mojca [0000-0003-4261-0424], Cordero, Elisa [0000-0001-7766-7266], Moreau, Richard [0000-0003-0862-403X], Boettler, Tobias, Marjot, Thomas, Newsome, Philip N., Mondelli, Mario U., Maticic, Mojca, Cordero-Matía, Elisa, Jalan, Rajiv, Moreau, Richard, Cornberg, Markus, Berg, Thomas, National Institutes of Health (US), National Health Service (UK), Boettler, Tobias [0000-0002-1195-055X], Maticic, Mojca [0000-0003-4261-0424], Cordero, Elisa [0000-0001-7766-7266], Moreau, Richard [0000-0003-0862-403X], Boettler, Tobias, Marjot, Thomas, Newsome, Philip N., Mondelli, Mario U., Maticic, Mojca, Cordero-Matía, Elisa, Jalan, Rajiv, Moreau, Richard, Cornberg, Markus, and Berg, Thomas

Abstract

During the early stages of the COVID-19 pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. In the meantime, many countries and healthcare systems have been, or are still overwhelmed by the pandemic, significantly impacting on the care of this group of patients, whilst others have started to return towards their usual routine. In addition, many studies have been published focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence the clinical course of COVID-19. While many aspects remain poorly understood, it has become increasingly evident that pre-existing liver diseases and liver injury during the course of the disease have to be kept in mind when caring for patients with COVID-19. Thus, this review should serve as an update on the previous position paper summarizing the evidence for liver disease involvement during COVID-19 and also provid

Published
2020

11. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper

Author

Boettler, Tobias [0000-0002-1195-055X], Maticic, Mojca [0000-0003-4261-0424], Cordero, Elisa [0000-0001-7766-7266], Cornberg, Markus [0000-0002-9141-8001], Boettler, Tobias, Newsome, Philip N., Mondelli, Mario U., Maticic, Mojca, Cordero-Matía, Elisa, Cornberg, Markus, Berg, Thomas, Boettler, Tobias [0000-0002-1195-055X], Maticic, Mojca [0000-0003-4261-0424], Cordero, Elisa [0000-0001-7766-7266], Cornberg, Markus [0000-0002-9141-8001], Boettler, Tobias, Newsome, Philip N., Mondelli, Mario U., Maticic, Mojca, Cordero-Matía, Elisa, Cornberg, Markus, and Berg, Thomas

Abstract

The coronavirus disease 2019 (COVID-19) pandemic poses an enormous challenge to healthcare systems in affected communities. Older patients and those with pre-existing medical conditions have been identified as populations at risk of a severe disease course. It remains unclear at this point to what extent chronic liver diseases should be considered as risk factors, due to a shortage of appropriate studies. However, patients with advanced liver disease and those after liver transplantation represent vulnerable patient cohorts with an increased risk of infection and/or a severe course of COVID-19. In addition, the current pandemic requires unusual allocation of healthcare resources which may negatively impact the care of patients with chronic liver disease that continue to require medical attention. Thus, the challenge hepatologists are facing is to promote telemedicine in the outpatient setting, prioritise outpatient contacts, avoid nosocomial dissemination of the virus to patients and healthcare providers, and at the same time maintain standard care for patients who require immediate medical attention.

Published
2020

22. Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

Author

Bruno, Savino, Cammà, Calogero, Di Marco, Vito, Rumi, Mariagrazia, Vinci, Maria, Camozzi, Mario, Rebucci, Chiara, Di Bona, Danilo, Colombo, Massimo, Craxì, Antonio, Mondelli, Mario U., Pinzello, Giovanbattista, Squadrito, Giovanni, BRUNO S, CAMMA' C, DI MARCO V, RUMI M, VINCI M, CAMOZZI M, REBUCCI C, DI BONA, COLOMBO M, CRAXI A, MONDELLI MU, and PINZELLO G

Subjects
Adult, Male, medicine.medical_specialty, Genotype, Combination therapy, Fibrosi, Hepacivirus, Alpha interferon, Interferon alpha-2, Antiviral Agents, Gastroenterology, Polyethylene Glycols, law.invention, chemistry.chemical_compound, Randomized controlled trial, law, Multicenter trial, Internal medicine, Ribavirin, medicine, Humans, Hepatology, biology, business.industry, fibrosis, Interferon-alpha, virus diseases, Drug Tolerance, Hepatitis C, Hepatitis C, Chronic, Middle Aged, biology.organism_classification, medicine.disease, Recombinant Proteins, digestive system diseases, chemistry, Immunology, Peginterferon alfa-2b, Female, Safety, business, medicine.drug
Abstract

We assessed the effectiveness and safety of an induction dose of peginterferon alfa-2b (PEG-IFN) plus ribavirin for initial treatment of patients with genotype 1 chronic HCV infection in a randomized, controlled, multicenter trial.Three hundred and eleven naïve patients infected with genotype 1 and chronic hepatitis were randomly assigned to 48-week treatment with PEG-IFN once weekly (80-100 micrograms depending on body weight for 8 weeks, followed by 50 micrograms for the next 40 weeks), or standard interferon alfa-2b (IFN) 6 million units on alternate days, both in combination with ribavirin (1000-1200 mg/day).PEG-IFN plus ribavirin significantly increased sustained virological response (SVR) compared with IFN plus ribavirin (41.1 vs. 29.3% respectively, P=0.030). Less patients discontinued PEG-IFN than IFN (19 vs. 31%, P=0.010). By logistic regression, SVR in the PEG-IFN group was independently associated with age50 years, and mild fibrosis at liver biopsy.Combination therapy with an induction dose of PEG-IFN was a more effective and better tolerated treatment for naïve patients with genotype 1 than combination therapy with high dose standard IFN. In patients aged less than 50 years with mild fibrosis this schedule achieves a very high rate of SVR.

Published
2004

23. Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review

Author

Visentini, Marcella, primary, Tinelli, Carmine, additional, Colantuono, Stefania, additional, Monti, Monica, additional, Ludovisi, Serena, additional, Gragnani, Laura, additional, Mitrevski, Milica, additional, Ranieri, Jessica, additional, Fognani, Elisa, additional, Piluso, Alessia, additional, Granata, Massimo, additional, De Silvestri, Annalisa, additional, Scotti, Valeria, additional, Mondelli, Mario U., additional, Zignego, Anna Linda, additional, Fiorilli, Massimo, additional, and Casato, Milvia, additional

Published
2015
Full Text
View/download PDF

25. Management of infections pre- and post-liver transplantation: Report of an AISF consensus conference

Author

Fagiuoli, Stefano, primary, Colli, Agostino, additional, Bruno, Raffaele, additional, Craxì, Antonio, additional, Gaeta, Giovanni Battista, additional, Grossi, Paolo, additional, Mondelli, Mario U., additional, Puoti, Massimo, additional, Sagnelli, Evangelista, additional, Stefani, Stefania, additional, Toniutto, Pierluigi, additional, and Burra, Patrizia, additional

Published
2014
Full Text
View/download PDF

26. Management of infections in cirrhotic patients: Report of a Consensus Conference

Author

Fagiuoli, Stefano, primary, Colli, Agostino, additional, Bruno, Raffaele, additional, Burra, Patrizia, additional, Craxì, Antonio, additional, Gaeta, Giovan Battista, additional, Grossi, Paolo, additional, Mondelli, Mario U., additional, Puoti, Massimo, additional, Sagnelli, Evangelista, additional, Stefani, Stefania, additional, and Toniutto, Pierluigi, additional

Published
2014
Full Text
View/download PDF

28. Natural killer cell dynamic profile is associated with treatment outcome in patients with chronic HCV infection

Author

Oliviero, Barbara, primary, Mele, Dalila, additional, Degasperi, Elisabetta, additional, Aghemo, Alessio, additional, Cremonesi, Eleonora, additional, Rumi, Maria Grazia, additional, Tinelli, Carmine, additional, Varchetta, Stefania, additional, Mantovani, Stefania, additional, Colombo, Massimo, additional, and Mondelli, Mario U., additional

Published
2013
Full Text
View/download PDF

31. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection

Author

Visentini, Marcella, primary, Ludovisi, Serena, additional, Petrarca, Antonio, additional, Pulvirenti, Federica, additional, Zaramella, Marco, additional, Monti, Monica, additional, Conti, Valentina, additional, Ranieri, Jessica, additional, Colantuono, Stefania, additional, Fognani, Elisa, additional, Piluso, Alessia, additional, Tinelli, Carmine, additional, Zignego, Anna Linda, additional, Mondelli, Mario U., additional, Fiorilli, Massimo, additional, and Casato, Milvia, additional

Published
2011
Full Text
View/download PDF

32. Enhanced B-cell differentiation and reduced proliferative capacity in chronic hepatitis C and chronic hepatitis B virus infections

Author

Oliviero, Barbara, primary, Cerino, Antonella, additional, Varchetta, Stefania, additional, Paudice, Enrica, additional, Pai, Somnath, additional, Ludovisi, Serena, additional, Zaramella, Marco, additional, Michelone, Giuseppe, additional, Pugnale, Paolo, additional, Negro, Francesco, additional, Barnaba, Vincenzo, additional, and Mondelli, Mario U., additional

Published
2011
Full Text
View/download PDF

37. Prospective study of natural killer cell phenotype in recurrent hepatitis C virus infection following liver transplantation

Author

Varchetta, Stefania, primary, Oliviero, Barbara, additional, Donato, M. Francesca, additional, Agnelli, Francesca, additional, Rigamonti, Cristina, additional, Paudice, Enrica, additional, Arosio, Eliana, additional, Berra, Mauro, additional, Rossi, Giorgio, additional, Tinelli, Carmine, additional, Fagnoni, Francesco F., additional, Colombo, Massimo, additional, Mavilio, Domenico, additional, and Mondelli, Mario U., additional

Published
2009
Full Text
View/download PDF

38. Statements from the Taormina expert meeting on occult hepatitis B virus infection

Author

Raimondo, Giovanni, primary, Allain, Jean-Pierre, additional, Brunetto, Maurizia R., additional, Buendia, Marie-Annick, additional, Chen, Ding-Shinn, additional, Colombo, Massimo, additional, Craxì, Antonio, additional, Donato, Francesco, additional, Ferrari, Carlo, additional, Gaeta, Giovanni B., additional, Gerlich, Wolfram H., additional, Levrero, Massimo, additional, Locarnini, Stephen, additional, Michalak, Thomas, additional, Mondelli, Mario U., additional, Pawlotsky, Jean-Michel, additional, Pollicino, Teresa, additional, Prati, Daniele, additional, Puoti, Massimo, additional, Samuel, Didier, additional, Shouval, Daniel, additional, Smedile, Antonina, additional, Squadrito, Giovanni, additional, Trépo, Christian, additional, Villa, Erica, additional, Will, Hans, additional, Zanetti, Alessandro R., additional, and Zoulim, Fabien, additional

Published
2008
Full Text
View/download PDF

40. Foreword

Author

Mondelli, Mario U, primary, de Franchis, Roberto, additional, and Colombo, Massimo, additional

Published
2008
Full Text
View/download PDF

50. HGV/GBV-C infection in liver transplant recipients: antibodies to the viral E2 envelope glycoprotein protect from de novo infection

Author

Silini, Enrico, primary, Belli, Luca, additional, Alberti, Albert B., additional, Asti, Margherita, additional, Cerino, Antonella, additional, Bissolati, Morena, additional, Rondinara, Gianfranco, additional, Carlis, Luciano De, additional, Forti, Domenico, additional, Mondelli, Mario U., additional, and Ideo, Gaetano, additional

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results